Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Mutagenesis ; 34(1): 67-82, 2019 03 06.
Artículo en Inglés | MEDLINE | ID: mdl-30189015

RESUMEN

(Quantitative) structure-activity relationship or (Q)SAR predictions of DNA-reactive mutagenicity are important to support both the design of new chemicals and the assessment of impurities, degradants, metabolites, extractables and leachables, as well as existing chemicals. Aromatic N-oxides represent a class of compounds that are often considered alerting for mutagenicity yet the scientific rationale of this structural alert is not clear and has been questioned. Because aromatic N-oxide-containing compounds may be encountered as impurities, degradants and metabolites, it is important to accurately predict mutagenicity of this chemical class. This article analysed a series of publicly available aromatic N-oxide data in search of supporting information. The article also used a previously developed structure-activity relationship (SAR) fingerprint methodology where a series of aromatic N-oxide substructures was generated and matched against public and proprietary databases, including pharmaceutical data. An assessment of the number of mutagenic and non-mutagenic compounds matching each substructure across all sources was used to understand whether the general class or any specific subclasses appear to lead to mutagenicity. This analysis resulted in a downgrade of the general aromatic N-oxide alert. However, it was determined there were enough public and proprietary data to assign the quindioxin and related chemicals as well as benzo[c][1,2,5]oxadiazole 1-oxide subclasses as alerts. The overall results of this analysis were incorporated into Leadscope's expert-rule-based model to enhance its predictive accuracy.


Asunto(s)
Óxidos N-Cíclicos/química , Daño del ADN/efectos de los fármacos , Mutágenos/química , Relación Estructura-Actividad Cuantitativa , Óxidos N-Cíclicos/toxicidad , Mutagénesis/efectos de los fármacos , Pruebas de Mutagenicidad , Mutágenos/toxicidad
2.
Regul Toxicol Pharmacol ; 102: 53-64, 2019 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-30562600

RESUMEN

The International Council for Harmonization (ICH) M7 guideline describes a hazard assessment process for impurities that have the potential to be present in a drug substance or drug product. In the absence of adequate experimental bacterial mutagenicity data, (Q)SAR analysis may be used as a test to predict impurities' DNA reactive (mutagenic) potential. However, in certain situations, (Q)SAR software is unable to generate a positive or negative prediction either because of conflicting information or because the impurity is outside the applicability domain of the model. Such results present challenges in generating an overall mutagenicity prediction and highlight the importance of performing a thorough expert review. The following paper reviews pharmaceutical and regulatory experiences handling such situations. The paper also presents an analysis of proprietary data to help understand the likelihood of misclassifying a mutagenic impurity as non-mutagenic based on different combinations of (Q)SAR results. This information may be taken into consideration when supporting the (Q)SAR results with an expert review, especially when out-of-domain results are generated during a (Q)SAR evaluation.


Asunto(s)
Contaminación de Medicamentos , Guías como Asunto , Mutágenos/clasificación , Relación Estructura-Actividad Cuantitativa , Industria Farmacéutica , Agencias Gubernamentales , Mutágenos/toxicidad , Medición de Riesgo
3.
Regul Toxicol Pharmacol ; 77: 1-12, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26879463

RESUMEN

Statistical-based and expert rule-based models built using public domain mutagenicity knowledge and data are routinely used for computational (Q)SAR assessments of pharmaceutical impurities in line with the approach recommended in the ICH M7 guideline. Knowledge from proprietary corporate mutagenicity databases could be used to increase the predictive performance for selected chemical classes as well as expand the applicability domain of these (Q)SAR models. This paper outlines a mechanism for sharing knowledge without the release of proprietary data. Primary aromatic amine mutagenicity was selected as a case study because this chemical class is often encountered in pharmaceutical impurity analysis and mutagenicity of aromatic amines is currently difficult to predict. As part of this analysis, a series of aromatic amine substructures were defined and the number of mutagenic and non-mutagenic examples for each chemical substructure calculated across a series of public and proprietary mutagenicity databases. This information was pooled across all sources to identify structural classes that activate or deactivate aromatic amine mutagenicity. This structure activity knowledge, in combination with newly released primary aromatic amine data, was incorporated into Leadscope's expert rule-based and statistical-based (Q)SAR models where increased predictive performance was demonstrated.


Asunto(s)
Aminas/toxicidad , Minería de Datos/métodos , Bases del Conocimiento , Mutagénesis , Pruebas de Mutagenicidad/métodos , Mutágenos/toxicidad , Aminas/química , Aminas/clasificación , Animales , Simulación por Computador , Bases de Datos Factuales , Humanos , Modelos Moleculares , Estructura Molecular , Mutágenos/química , Mutágenos/clasificación , Reconocimiento de Normas Patrones Automatizadas , Relación Estructura-Actividad Cuantitativa , Medición de Riesgo
4.
Regul Toxicol Pharmacol ; 77: 13-24, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26877192

RESUMEN

The ICH M7 guideline describes a consistent approach to identify, categorize, and control DNA reactive, mutagenic, impurities in pharmaceutical products to limit the potential carcinogenic risk related to such impurities. This paper outlines a series of principles and procedures to consider when generating (Q)SAR assessments aligned with the ICH M7 guideline to be included in a regulatory submission. In the absence of adequate experimental data, the results from two complementary (Q)SAR methodologies may be combined to support an initial hazard classification. This may be followed by an assessment of additional information that serves as the basis for an expert review to support or refute the predictions. This paper elucidates scenarios where additional expert knowledge may be beneficial, what such an expert review may contain, and how the results and accompanying considerations may be documented. Furthermore, the use of these principles and procedures to yield a consistent and robust (Q)SAR-based argument to support impurity qualification for regulatory purposes is described in this manuscript.


Asunto(s)
Pruebas de Carcinogenicidad/métodos , Daño del ADN , Minería de Datos/métodos , Mutagénesis , Pruebas de Mutagenicidad/métodos , Mutágenos/toxicidad , Toxicología/métodos , Animales , Pruebas de Carcinogenicidad/normas , Simulación por Computador , Bases de Datos Factuales , Adhesión a Directriz , Guías como Asunto , Humanos , Modelos Moleculares , Estructura Molecular , Pruebas de Mutagenicidad/normas , Mutágenos/química , Mutágenos/clasificación , Formulación de Políticas , Relación Estructura-Actividad Cuantitativa , Medición de Riesgo , Toxicología/legislación & jurisprudencia , Toxicología/normas
5.
Methods Mol Biol ; 1425: 383-430, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27311475

RESUMEN

Toxicity databases are a useful resource to support hazard and risk assessment. They are used to retrieve historical studies for compounds of interest and to support toxicity predictions where no data exists. Toxicity predictions are either based upon study results from similar chemicals or prediction models built from these databases.


Asunto(s)
Bases de Datos Farmacéuticas , Fenómenos Toxicológicos , Internet , Relación Estructura-Actividad Cuantitativa , Interfaz Usuario-Computador
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA